Mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis, found the latest study of the drug. The study conducted by Claus Bachert and colleagues at the Upper Airways Research Laboratory at Ghent University Hospital in Ghent, Belgium, showed that mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis with nasal polyps, regardless of comorbid asthma or aspirin-exacerbated respiratory disease. The researchers said that they conducted subgroup analyses of the study to stratify the efficacy of the drug based on the presence of comorbid asthma, comorbid aspirin-exacerbated respiratory disease (AERD) and baseline blood eosinophil count. The findings, published in The journal of Allergy and Clinical Immunology, showed that the analysis included 407 patients, out of which 50.5 percent patients had a one point or greater improvement from baseline in their total endoscopic NP score at week 52 than those who received placebo (28.4%).